BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced an upcoming presentation at the ATS 2023 Respiratory Innovation Summit being held in Washington D.C. May 19-20, 2023. Robert Clarke, PhD, Chief Executive Officer of Kinaset, will deliver an oral and poster presentation on the latest clinical progress of Kinaset’s lead candidate, KN-002, a novel, pan-JAK inhibitor being advanced for the treatment of moderate to severe asthma.
Presentation Details:
Poster Title: Kinaset Therapeutics: A Clinical-Stage Respiratory Disease-Focused Company
Session Title: Showcase One: Asthma, COPD, and Airway Inflammation Innovators
Session Date and Time: Saturday, May 20 at 8:30 a.m. ET
Location: Marriott Marquis Washington
More information on the ATS 2023 Respiratory Innovation Summit can be found here.
About Kinaset Therapeutics, Inc.
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. The Company’s lead clinical candidate KN-002 is a novel, pan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhaled route of administration. KN-002 is currently being evaluated in a Phase 1b clinical study involving patients with mild to severe asthma and those with COPD (NCT05006521). With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company. See more information at the Company’s website.
